CG
CCCC icon

Cutler Group’s C4 Therapeutics CCCC Stock Holding History

Cutler Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,600
Closed -$8K – 2410
2023
Q4 		$8K Buy
+10,600
New +$24.2K ﹤0.01% 2503
2022
Q2 		– Sell
-500
Closed -$1K – 5015
2022
Q1 		$1K Buy
+500
New +$12.1K ﹤0.01% 4906

Other funds holding CCCC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's CCCC Position: Q1 2024 in Review

Cutler Group reduced its C4 Therapeutics (CCCC) stake by 69% in Q1 2024, selling an estimated $14K and leaving 800 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Cutler Group first reported a position in CCCC in Q1 2022 and has held it in 3 quarters since. The position peaked at $309K in Q1 2022. 106 funds tracked by Wall St. Rank hold CCCC as of Q1 2024.

  • Cutler Group held 800 shares of C4 Therapeutics worth $6K as of Q1 2024.
  • Cutler Group sold 1,800 C4 Therapeutics shares in Q1 2024, an estimated $14K.
  • C4 Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1480 holding.
  • Cutler Group first reported a position in C4 Therapeutics in Q1 2022 and has held it in 3 quarters since.
  • Cutler Group's C4 Therapeutics position peaked at $309K in Q1 2022.
  • 106 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.